Zdrowie i gospodarka · 16/03/2021
FDA Reopens Comment Period for Draft Guidance on Proprietary Names for Human Nonprescription Drugs
The FDA is extending the comment period for its draft guidance on developing proprietary names for human nonprescription drugs, allowing more time for industry stakeholders to submit feedback